CCR8 and neoplasm: In contrast, IPG0521m, which bound murine CCR8 with high affinity and potently blocked CCR8-mediated signaling in different assays, including β-arrestin assay and chemotaxis assay, with a nanomolar range of IC50, was shown to inhibit tumor growth in a dose-dependent manner.